F-star Therapeutics Appoints Dr. Edward Benz and Mr. Geoff Race to Board of Directors
F-star Therapeutics (“F-star”), a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2™ ) antibodies, today announces the appointments of Dr. Edward Benz and Mr. Geoff Race to its Board of Directors, further strengthening the depth and breadth of its clinical and industry expertise.
Dr. Edward Benz is a renowned leader in the field of oncology with a distinguished career spanning more than 40 years across industry and academia. Dr. Benz is President and Chief Executive Officer Emeritus of the Dana-Farber Cancer Institute, Boston, MA. He is also the Richard and Susan Smith Distinguished Professor of Medicine, Professor of Pediatrics, Professor of Genetics and Faculty Dean Emeritus for Oncology at Harvard Medical School. Former associate editor of the New England Journal of Medicine, Dr. Benz has authored over 300 peer-reviewed publications and holds several senior positions on various academic boards. He received his Doctor of Medicine from Harvard Medical School, holds an M.A. from Yale University and a B.S. from Princeton University.
Mr. Geoff Race, FCMA, MBA, has more than 20 years of experience at both the Chief Financial and Chief Executive Officer level in the life sciences industry. He has significant global transactional and operational expertise across public and private companies He is the Executive Vice President, Chief Financial Officer and Chief Business Officer of Minerva Neurosciences Inc, a company he co-founded in 2013 through the merger of Cyrenaic Inc and Sonkei Inc. Previously, Mr. Race served as Chief Executive Officer of Funxional Therapeutics Ltd, an early-stage research company focused on the treatment of inflammatory diseases. Mr. Race earned his MBA from Durham University Business School, UK, and is a Fellow of the Chartered Institute of Management Accountants.
Eliot Forster, CEO of F-star said: “I am excited to welcome Ed and Geoff to our Board. Their in-depth clinical and industry knowledge and wealth of international experience in medical oncology and biotechnology will be invaluable to F-star as we continue to progress our lead program, FS118, through the clinic, and as we advance two new bispecifics from our pipeline into patients.”
Dr. Edward Benz said: “F-star’s focus on hard-to-treat cancers and the Company’s rapid advancement in the clinic makes it a very exciting time to join the Board of Directors. Breakthroughs in immuno-oncology have revolutionized cancer treatment, but there continues to be a pressing need to develop new medicines, like those arising from F-star’s novel bispecific technology. I look forward to working alongside the leadership team and scientific staff as they work towards the goal of improving treatment outcomes for patients suffering from difficult-to-treat cancers.”
Geoff Race said: “I’m delighted to be joining F-star’s Board of Directors at such a crucial time in the Company’s development. Through the combination of F-star’s world-class scientific leadership team, experienced management team and differentiated bispecific platform, I believe we have a real opportunity to develop more efficacious therapies for patients with cancer and create significant shareholder value.”
- END -
F-star is a clinical-stage immuno-oncology company singularly focused on transforming the lives of patients with cancer through the development of its innovative tetravalent mAb2 bispecific antibodies. With four distinct binding sites in a natural human antibody format, F-star believes its proprietary approach will overcome many of the challenges facing current immuno-oncology therapies. F-star’s vision is to transform the treatment of cancer through the development of differentiated and well-tolerated mAb2 bispecific antibodies, which are designed to simultaneously address multiple immune evasion pathways that limit the effect of current immuno-oncology therapies.
mAb2 ™ is a trademark of F-star.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GA-TPG22.1.2020 03:12:05 CET | Press release
CollabNet VersionOne and XebiaLabs Combine to Create Integrated Agile DevOps Platform
CA-GILEAD-SCIENCES,-INC.21.1.2020 23:32:09 CET | Press release
Gilead Sciences to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 4, 2020
BERMUDA-BUSINESS-DEVLPMT21.1.2020 23:12:09 CET | Press release
Bermuda Further Enhances Its International Appeal as Incorporated Segregated Accounts Companies Legislation Comes Into Effect
NASPERS-LIMITED21.1.2020 18:35:04 CET | Press release
Naspers Limited Launches the Sale of c. 22 Million N Ordinary Shares of Prosus N.V. Through an Accelerated Bookbuild Offering to Institutional Investors
NV-RIMINI-STREET21.1.2020 15:02:08 CET | Press release
Hearing Australia Shifts its E-Business Support and Maintenance to Rimini Street
CA-SD-ASSOCIATION21.1.2020 14:57:07 CET | Press release
SD & microSD Memory Cards - the World’s First Choice in Memory Cards - 20 Years of Innovation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom